These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12679700)

  • 41. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
    Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
    Marcelin AG; Cohen-Codar I; King MS; Colson P; Guillevic E; Descamps D; Lamotte C; Schneider V; Ritter J; Segondy M; Peigue-Lafeuille H; Morand-Joubert L; Schmuck A; Ruffault A; Palmer P; Chaix ML; Mackiewicz V; Brodard V; Izopet J; Cottalorda J; Kohli E; Chauvin JP; Kempf DJ; Peytavin G; Calvez V
    Antimicrob Agents Chemother; 2005 May; 49(5):1720-6. PubMed ID: 15855487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
    AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
    Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
    Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
    J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J; Santos JR; Negredo E; Miranda C; Videla S; Clotet B
    J Antimicrob Chemother; 2007 Aug; 60(2):436-9. PubMed ID: 17556354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    Chadwick EG; Capparelli EV; Yogev R; Pinto JA; Robbins B; Rodman JH; Chen J; Palumbo P; Serchuck L; Smith E; Hughes M;
    AIDS; 2008 Jan; 22(2):249-55. PubMed ID: 18097227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
    De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Hoetelmans RM; Cauda R
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):359-66. PubMed ID: 15097152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
    AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
    Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
    HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
    Barragan P; Podzamczer D
    Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.